<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444622</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-032-MCRC3-STIM</org_study_id>
    <nct_id>NCT04444622</nct_id>
  </id_info>
  <brief_title>Immunotherapy for Third Line Metastatic Colorectal Cancer</brief_title>
  <acronym>STIMVAX</acronym>
  <official_title>Phase IIB Open-Label Study to Assess the Safety and Efficacy of STIMVAX® as Third-line Therapy for Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mirror Biologics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIB multi-site, open label study of a next generation immunotherapy for&#xD;
      third-line MSI-S metastatic colorectal cancer using an &quot;off-the-shelf&quot;, non-genetically&#xD;
      manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IIB open label immunotherapy protocol called &quot;StimVax&quot;. The protocol design&#xD;
      is based upon information obtained from a previous Phase IIA dose level and dose frequency&#xD;
      ranging study. The population targeted is MSI-S metastatic colorectal cancer previously&#xD;
      treated with two lines of chemotherapy regimens, one containing oxaliplatin and the other&#xD;
      containing irinotecan. This population is not considered to be responsive to immunotherapy.&#xD;
&#xD;
      The study drug is called &quot;AlloStim&quot;. AlloStim is an &quot;off-the-shelf&quot;,&#xD;
      non-genetically-manipulated, living immune cell immunotherapy. AlloStim is derived from&#xD;
      precursors purified from the blood of healthy donors and grown and differentiated in&#xD;
      specialized bioreactors in the laboratory. Because the donors are intentionally mis-matched&#xD;
      to the host, AlloStim is completely eliminated by the host in a non-toxic rejection response&#xD;
      within 24h of administration.&#xD;
&#xD;
      Unlike autologous immune cell therapies, like CAR-T cells or TIL cells, AlloStim is&#xD;
      allogeneic and is not intended to directly kill tumors. Rather, the novel AlloStim mechanism&#xD;
      is designed to modify and train the host immune system to kill tumors and prevent tumor&#xD;
      growth and spread. Uniquely, the AlloStim mechanism is also designed to increase Th1/Th2&#xD;
      balance, activate innate effector cells (such as NK and NKT), counter-regulate the immune&#xD;
      suppressive and immune evasion mechanisms that tumors use to evade immune elimination both&#xD;
      systemically and in the tumor microenvironment.&#xD;
&#xD;
      The AlloStim mechanism creates self-amplifying waves of temporal and spatial immune effects&#xD;
      that can lead to an initial non-specific cellular innate NK cell immune response followed by&#xD;
      a tumor-specific killer T-cell immune response specific for the host tumor through a&#xD;
      combination of immune processes called &quot;allo-priming&quot; and &quot;in-situ vaccination&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">February 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>date of death from any cause, whichever came first, assessed up to 12 months from accrual</time_frame>
    <description>measurement of the survival on experimental treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidents of Adverse Events (AE)</measure>
    <time_frame>day 0 to 1 year</time_frame>
    <description>to evaluate safety and tolerability</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>AlloStim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AlloStim is administered in three cycles:&#xD;
Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®&#xD;
Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®&#xD;
Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors</description>
    <arm_group_label>AlloStim</arm_group_label>
    <other_name>StimVax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males and female subjects aged 18-80 years at screening visit&#xD;
&#xD;
          2. Pathologically confirmed diagnosis of colorectal adenocarcinoma&#xD;
&#xD;
          3. Presenting with metastatic disease:&#xD;
&#xD;
               -  Primary can be intact or previously resected&#xD;
&#xD;
               -  Preferably with metastasis to the liver or other location for safe percutaneous&#xD;
                  biopsy&#xD;
&#xD;
          4. Previous treatment failure of two previous lines of active systemic chemotherapy:&#xD;
&#xD;
               -  Previous chemotherapy must have included an oxaliplatin-containing (e.g. FOLFOX)&#xD;
                  and an irinotecan-containing (e.g. FOLFIRI) regimen&#xD;
&#xD;
               -  With or without bevacizumab&#xD;
&#xD;
               -  Administered in adjuvant setting or for treatment of metastatic disease&#xD;
&#xD;
               -  If KRAS wild type, must have at least one prior anti-EGFR therapy&#xD;
&#xD;
               -  Treatment failure can be due to disease progression or toxicity&#xD;
&#xD;
               -  Disease progression on second line therapy must be documented radiologically and&#xD;
                  must have occurred during or within 30 days following the last administration of&#xD;
                  treatment for metastatic disease&#xD;
&#xD;
          5. ECOG performance score: 0-1&#xD;
&#xD;
          6. Adequate hematological function:&#xD;
&#xD;
               -  Absolute granulocyte count ≥ 1,200/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  PT/INR ≤ 1.5 or correctable to &lt;1.5 at time of interventional procedures&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (may be corrected by transfusion)&#xD;
&#xD;
          7. Adequate Organ Function:&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 times ULN *&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or (SGOT) ≤ 2.5 times ULN *&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or (SGPT) ≤ 2.5 times ULN * *or ≤5x ULN if liver&#xD;
                  involvement&#xD;
&#xD;
          8. EKG without clinically relevant abnormalities&#xD;
&#xD;
          9. Female subjects: Not pregnant or lactating&#xD;
&#xD;
         10. Patients with child bearing potential must agree to use adequate contraception&#xD;
&#xD;
         11. Study specific informed consent in the native language of the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. high frequency microsatellite instability (MSI-H)&#xD;
&#xD;
          2. Bowel obstruction or high risk for obstruction if tumors become inflamed&#xD;
&#xD;
          3. Moderate or severe ascites requiring medical intervention&#xD;
&#xD;
          4. Clinical evidence or radiological evidence of brain metastasis or leptomeningeal&#xD;
             involvement&#xD;
&#xD;
          5. Peritoneal carcinomatosis&#xD;
&#xD;
          6. Symptomatic asthma or COPD&#xD;
&#xD;
          7. Pulmonary lymphangitis or symptomatic pleural effusion (grade ≥ 2) that results in&#xD;
             pulmonary dysfunction requiring active treatment; or, oxygen saturation &lt;92% on room&#xD;
             air&#xD;
&#xD;
          8. Bevacizumab (Avastin®) treatment within 6 weeks of baseline scheduled biopsy procedure&#xD;
&#xD;
          9. Any of the following mood disorders: active major depressive episode, history of&#xD;
             suicidal attempt or ideation&#xD;
&#xD;
         10. Prior allogeneic bone marrow/stem cell or solid organ transplant&#xD;
&#xD;
         11. Chronic use (&gt; 2 weeks) of greater than physiologic doses of a corticosteroid agent&#xD;
             (dose equivalent to &gt; 5 mg/day of prednisone) within 30 days of the first day of study&#xD;
             drug treatment&#xD;
&#xD;
               -  Topical corticosteroids are permitted&#xD;
&#xD;
         12. Prior diagnosis of an active autoimmune disease (e.g., rheumatoid arthritis, multiple&#xD;
             sclerosis, autoimmune thyroid disease, uveitis).&#xD;
&#xD;
               -  Well controlled Type I diabetes allowed&#xD;
&#xD;
         13. Prior experimental therapy&#xD;
&#xD;
         14. History of blood transfusion reactions&#xD;
&#xD;
         15. Progressive viral or bacterial infection&#xD;
&#xD;
               -  All infections must be resolved and the subject must remain afebrile for seven&#xD;
                  days without antibiotics prior to being placed on study&#xD;
&#xD;
         16. Cardiac disease of symptomatic nature&#xD;
&#xD;
         17. History of HIV positivity or AIDS&#xD;
&#xD;
         18. Concurrent medication known to interfere with platelet function or coagulation (e.g.,&#xD;
             aspirin, ibuprofen, clopidogrel, or warfarin) unless such medications can be&#xD;
             discontinued for an appropriate time period based on the drug half-life and known&#xD;
             activity (e.g., aspirin for 7 days) prior to biopsy procedures&#xD;
&#xD;
         19. History of severe hypersensitivity to monoclonal antibody drugs&#xD;
&#xD;
         20. Psychiatric or addictive disorders or other condition that, in the opinion of the&#xD;
             investigator, would preclude study participation.&#xD;
&#xD;
         21. Subjects that lack ability to provide consent for themselves.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kim Demonte</last_name>
    <phone>732-630-9059</phone>
    <email>axellaresearch@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thu Bui, MHA</last_name>
    <phone>619-227-4872</phone>
    <email>thu@immunovative.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hirschfield Oncology Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Witkowski</last_name>
      <phone>718-732-4050</phone>
      <email>karla@honcology.com</email>
    </contact>
    <investigator>
      <last_name>Azriel Hirschfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpha Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>281-324-0575</phone>
      <email>info@alpharesearchinst.com</email>
    </contact>
    <investigator>
      <last_name>Amir A Rasheed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan P Glombicki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.</citation>
    <PMID>18054441</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>cancer vaccine</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>AlloStim</keyword>
  <keyword>MSI-S</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

